Amgen AMGN Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 266.2%+17.8pp | 260.9%+9.2pp | 255.2%-5.0pp | 249.5%-23.8pp | 248.3%-35.8pp | |
| Operating margin | 100.7%+18.0pp | 94.1%+9.7pp | 91.1%+0.4pp | 86.1%-18.5pp | 82.7%-37.7pp | |
| Net margin | 80.4%+27.6pp | 76.8%+28.7pp | 68.1%+8.4pp | 61.6%-13.3pp | 52.7%-42.0pp | |
| Returns | ||||||
| Return on equity | 388.3%+110pp | 392.6%+148pp | 354.1%+40.7pp | 328.1%-63.4pp | 278.2%-237pp | |
| Return on invested capital | 48.5%+12.6pp | 44.5%+9.8pp | 41.9%+4.2pp | 38.9%-4.4pp | 35.9%-15.0pp | |
| Efficiency | ||||||
| Asset turnover | 1.6×+0.2× | 1.6×+0.2× | 1.5×+0.1× | 1.5×+0.1× | 1.4×+0.1× | |
| Liquidity | ||||||
| Current ratio | 5×0.0× | 4.9×-0.4× | 5×-0.6× | 5.1×-2.1× | 5×-3.7× | |
| Leverage | ||||||
| Debt-to-equity | 25.9×-12.3× | 28.9×-12.8× | 32.8×-9.0× | 35.2×-6.5× | 38.2×-2.0× | |
| Net debt / EBITDA | 15.4×-4.3× | 16.1×-4.7× | 16.9×-4.6× | 18.2×-3.0× | 19.7×-0.7× | |
| Per Share | ||||||
| Book value per share | $64.34+36.4% | $58.92+30.7% | $53.81+17.5% | $49.95+8.3% | $47.18-1.3% | |
| Valuation | ||||||
| Market capitalization | $667.05B+2.9% | $644.75B+1.8% | $608.6B-6.0% | $629.81B+1.9% | $648.21B+13.9% | |
| Price / earnings | 91.4×-65.5× | 95.3×-73.9× | 106.7×-51.2× | 125.9×-10.1× | 156.9×+59.6× | |
| Price / sales | 18.4×-1.4× | 18.2×-1.9× | 17.6×-3.8× | 18.7×-2.7× | 19.8×-0.6× | |
| Price / book | 76.9×-25.2× | 83.2×-22.3× | 86.7×-19.7× | 93.9×-8.2× | 102.1×+10.7× | |
| EV / EBITDA | 61.7×-11.3× | 63×-11.5× | 62.3×-14.8× | 67.5×-6.2× | 73×+5.8× | |
| Dividend yield | 12.3%+0.4pp | 12.5%+0.5pp | 13%+1.5pp | 12.5%+0.6pp | 11.9%-0.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Amgen's profit margins?
- Amgen (AMGN) runs a 68.3% gross margin and a 28.4% operating margin, with a 21.0% net margin.
- Where do Amgen's ratios come from?
- Every ratio is computed from Amgen's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
